8V52

Crystal structure of 2A10 Fab bound to Human TGF-beta3

8V52 の概要

• エントリーDOI: 10.2210/pdb8v52/pdb
• 分子名称: Transforming growth factor beta-3, 2A10 Fab Light chain, 2A10 Fab Heavy Chain, ... (4 entities in total)
• 機能のキーワード: tgf beta, 2a10, complex, fab, cytokine, cytokine-immune system complex, cytokine/immune system
• 由来する生物種: Homo sapiens (human); 詳細
• タンパク質・核酸の鎖数: 6
• 化学式量合計: 121433.79

構造登録者

Yin, J.,Lupardus, P.J. (登録日: 2023-11-30, 公開日: 2024-04-10, 最終更新日: 2024-11-13)

主引用文献

Sun, T.,Vander Heiden, J.A.,Gao, X.,Yin, J.,Uttarwar, S.,Liang, W.C.,Jia, G.,Yadav, R.,Huang, Z.,Mitra, M.,Halpern, W.,Bender, H.S.,Brightbill, H.D.,Wu, Y.,Lupardus, P.,Ramalingam, T.,Arron, J.R.
Isoform-selective TGF-beta 3 inhibition for systemic sclerosis.
Med, 5:132-147.e7, 2024

PubMed Abstract: Transforming growth factor β (TGF-β) is implicated as a key mediator of pathological fibrosis, but its pleiotropic activity in a range of homeostatic functions presents challenges to its safe and effective therapeutic targeting. There are three isoforms of TGF-β, TGF-β1, TGF-β2, and TGF-β3, which bind to a common receptor complex composed of TGF-βR1 and TGF-βR2 to induce similar intracellular signals in vitro. We have recently shown that the cellular expression patterns and activation thresholds of TGF-β2 and TGF-β3 are distinct from those of TGF-β1 and that selective short-term TGF-β2 and TGF-β3 inhibition can attenuate fibrosis in vivo without promoting excessive inflammation. Isoform-selective inhibition of TGF-β may therefore provide a therapeutic opportunity for patients with chronic fibrotic disorders.

PubMed: 38272035
DOI: 10.1016/j.medj.2023.12.011

実験手法

X-RAY DIFFRACTION (2.5 Å)